A citation-based method for searching scientific literature

Nienke M A Idzerda, Bergur V Stefansson, Michelle J Pena, David C Sjostrom, David C Wheeler, Hiddo J L Heerspink. Nephrol Dial Transplant 2020
Times Cited: 5







List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
370
40

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
40

The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers.
P A Smink, Y Miao, M J C Eijkemans, S J L Bakker, I Raz, H-H Parving, J Hoekman, D E Grobbee, D de Zeeuw, H J Lambers Heerspink. Clin Pharmacol Ther 2014
17
40

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.
P A Smink, J Hoekman, D E Grobbee, M J C Eijkemans, H-H Parving, F Persson, H Ibsen, L Lindholm, K Wachtell, D de Zeeuw,[...]. Eur J Prev Cardiol 2014
14
40

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Bauke Schievink, Dick de Zeeuw, Paul A Smink, Dennis Andress, John J Brennan, Blai Coll, Ricardo Correa-Rotter, Fan Fan Hou, Donald Kohan, Dalane W Kitzman,[...]. Eur J Prev Cardiol 2016
19
40

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Nienke M A Idzerda, Lindsay E Clegg, Adrian F Hernandez, George Bakris, Robert C Penland, David W Boulton, M Angelyn Bethel, Rury R Holman, Hiddo J L Heerspink. Diabetes Obes Metab 2020
3
66

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Bauke Schievink, Dick de Zeeuw, Hans-Henrik Parving, Peter Rossing, Hiddo Jan Lambers Heerspink. Br J Clin Pharmacol 2015
25
40

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
676
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
20

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
Xinfang Xie, Emily Atkins, Jicheng Lv, Alexander Bennett, Bruce Neal, Toshiharu Ninomiya, Mark Woodward, Stephen MacMahon, Fiona Turnbull, Graham S Hillis,[...]. Lancet 2016
458
20

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Honghong Zou, Baoqin Zhou, Gaosi Xu. Cardiovasc Diabetol 2017
32
20

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
166
20

Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS).
S Katayama, T Moriya, S Tanaka, S Tanaka, Y Yajima, H Sone, S Iimuro, Y Ohashi, Y Akanuma, N Yamada. Diabetologia 2011
47
20

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
312
20

Plasmin in nephrotic urine activates the epithelial sodium channel.
Per Svenningsen, Claus Bistrup, Ulla G Friis, Marko Bertog, Silke Haerteis, Bettina Krueger, Jane Stubbe, Ole Nørregaard Jensen, Helle C Thiesson, Torben R Uhrenholt,[...]. J Am Soc Nephrol 2009
154
20

Oxidative stress in obesity and metabolic syndrome in children and adolescents.
Maria Felicia Faienza, Ruggiero Francavilla, Rocco Goffredo, Annamaria Ventura, Flaviana Marzano, Gianvito Panzarino, Grazia Marinelli, Luciano Cavallo, Giovanna Di Bitonto. Horm Res Paediatr 2012
43
20

Diabetes and Hypertension: A Position Statement by the American Diabetes Association.
Ian H de Boer, Sripal Bangalore, Athanase Benetos, Andrew M Davis, Erin D Michos, Paul Muntner, Peter Rossing, Sophia Zoungas, George Bakris. Diabetes Care 2017
171
20

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press 2016
50
20


SGLT2 inhibitors and the kidney: Effects and mechanisms.
V Tsimihodimos, T D Filippatos, M S Elisaf. Diabetes Metab Syndr 2018
16
20


Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide.
John Powles, Saman Fahimi, Renata Micha, Shahab Khatibzadeh, Peilin Shi, Majid Ezzati, Rebecca E Engell, Stephen S Lim, Goodarz Danaei, Dariush Mozaffarian. BMJ Open 2013
369
20

Proteasuria-The impact of active urinary proteases on sodium retention in nephrotic syndrome.
Ferruh Artunc, Matthias Wörn, Anja Schork, Bernhard N Bohnert. Acta Physiol (Oxf) 2019
16
20

Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche, Ferruh Artunc. Cardiovasc Diabetol 2019
40
20

L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
Tomohiko Kanaoka, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Tetsuya Fujikawa, Yuko Tsurumi-Ikeya, Akinobu Maeda,[...]. Int J Mol Sci 2013
9
20

Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Wenying Yang, Linong Ji, Zhiguang Zhou, Valerie A Cain, Kristina M Johnsson, C David Sjöström. J Diabetes 2017
8
20

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
203
20

Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study.
Masahiro Kikuya, Takayoshi Ohkubo, Hirohito Metoki, Kei Asayama, Azusa Hara, Taku Obara, Ryusuke Inoue, Haruhisa Hoshi, Junichiro Hashimoto, Kazuhito Totsune,[...]. Hypertension 2008
245
20

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
Li Tang, Yuanyuan Wu, Mi Tian, C David Sjöström, Ulrika Johansson, Xiao-Rong Peng, David M Smith, Yufeng Huang. Am J Physiol Endocrinol Metab 2017
37
20


Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants.
Rudolph Schutte, Lutgarde Thijs, Kei Asayama, José Boggia, Yan Li, Tine W Hansen, Yan-Ping Liu, Masahiro Kikuya, Kristina Björklund-Bodegård, Takayoshi Ohkubo,[...]. Am J Hypertens 2013
20
20

Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.
Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
47
20

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Sergei Petrykiv, C David Sjöström, Peter J Greasley, John Xu, Frederik Persson, Hiddo J L Heerspink. Clin J Am Soc Nephrol 2017
69
20

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Ann Intern Med 2012
283
20

Prognostic significance of day-by-day variability of home blood pressure on progression to macroalbuminuria in patients with diabetes.
Emi Ushigome, Shinobu Matsumoto, Chikako Oyabu, Noriyuki Kitagawa, Toru Tanaka, Goji Hasegawa, Masayoshi Ohnishi, Sei Tsunoda, Hidetaka Ushigome, Isao Yokota,[...]. J Hypertens 2018
6
20


Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases.
Ryu Kobayashi, Kouichi Tamura, Hiromichi Wakui, Masato Ohsawa, Kengo Azushima, Sona Haku, Kazushi Uneda, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi,[...]. Clin Exp Hypertens 2016
7
20


SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
M V Karg, A Bosch, D Kannenkeril, K Striepe, C Ott, M P Schneider, F Boemke-Zelch, P Linz, A M Nagel, J Titze,[...]. Cardiovasc Diabetol 2018
54
20

The Prevalence and Management of Diabetic Nephropathy in Asia.
Yasuhiko Tomino, Tomohito Gohda. Kidney Dis (Basel) 2015
19
20

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
H J L Heerspink, E Johnsson, I Gause-Nilsson, V A Cain, C D Sjöström. Diabetes Obes Metab 2016
107
20

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Hiddo J L Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic. J Am Soc Nephrol 2017
157
20

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Takashi Iizuka, Kotaro Iemitsu, Masahiro Takihata, Masahiko Takai, Shigeru Nakajima, Nobuaki Minami, Shinichi Umezawa, Akira Kanamori, Hiroshi Takeda, Takehiro Kawata,[...]. J Clin Med Res 2016
30
20

Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes.
Shin-ichi Araki, Masakazu Haneda, Daisuke Koya, Hideki Hidaka, Toshiro Sugimoto, Motohide Isono, Keiji Isshiki, Masami Chin-Kanasaki, Takashi Uzu, Atsunori Kashiwagi. Diabetes 2007
100
20


The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
Mai Yanagi, Kouichi Tamura, Tetsuya Fujikawa, Hiromichi Wakui, Tomohiko Kanaoka, Masato Ohsawa, Kengo Azushima, Akinobu Maeda, Hiroyuki Kobori, Satoshi Umemura. Hypertens Res 2013
17
20

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
128
20


The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Sergei I Petrykiv, Gozewijn D Laverman, Dick de Zeeuw, Hiddo J L Heerspink. Diabetes Obes Metab 2017
44
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.